Form 4: Armata Pharmaceuticals Director Acquires Stock Options

Todd C. Peterson, a director of Armata Pharmaceuticals, acquired stock options on March 14, 2024.

Summary

• On March 14, 2024, Todd C. Peterson, a director of Armata Pharmaceuticals, acquired stock options.
• He acquired 39,666 stock options with an exercise price of $3.38, vesting upon the company's 2024 annual shareholders meeting, contingent on continuous service.
• He also acquired 54,343 stock options with an exercise price of $3.38, vesting 50% on March 14, 2025, and 50% on March 14, 2026, subject to continuous service.
• Following these transactions, Peterson directly owns 94,009 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither inherently positive nor negative.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the holdings and transactions of company insiders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry as a form of compensation and incentive.
• The vesting schedules and exercise prices are generally aligned with industry norms to motivate long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment, as it signals confidence in the company's future.

Key Dates